Financial Performance Expectations - The company expects a net profit attributable to shareholders of -34 million to -41 million CNY for the first half of 2024 [3]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be -48 million to -55 million CNY [4]. - Estimated operating revenue for the first half of 2024 is between 140 million to 170 million CNY, with main business revenue expected to be 136 million to 166 million CNY [4]. - The net profit for the same period last year was -69.72 million CNY, indicating an improvement in the current year's performance [5]. Losses and Mitigation Strategies - The company reported a loss primarily due to decreased gross margins from centralized procurement, which could not cover the period expenses [7]. - The company has increased efforts in promoting centralized procurement products and maximizing production capacity to mitigate losses [7]. - The company aims to enhance cost control and operational efficiency to improve financial performance moving forward [7]. Financial Data and Caution - The preliminary financial data has not been audited by registered accountants, and investors are advised to be cautious [8]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast [8]. - The data provided is preliminary and the final financial figures will be disclosed in the official half-year report [9].
灵康药业(603669) - 2024 Q2 - 季度业绩预告